M3814: Clinical Trials

4 trials of M3814, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 1 completed. 4 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Active not recruiting 3, Completed 1
Phase 24Active not recruiting 3, Completed 1

Follow M3814: new trials by email Literature Review of M3814 trials Research Report on M3814

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)922021-01-112026-11-12
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)902020-10-142026-11-12
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)1032020-04-072026-11-12
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg - Locally Advanced Rectal Cancer
Phase 1 / Phase 2CompletedEMD Serono Research & Development Institute, Inc.192019-03-202023-03-21

Conditions studied

Cholangiocarcinoma (1)  ·  Gallbladder Neoplasms (1)  ·  Lymphatic Metastasis (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  EMD Serono Research & Development Institute, Inc. (1)

Countries

United States (4)  ·  Spain (1)

Top investigators

Kristen R Spencer (1)  ·  Russell K Pachynski (1)  ·  Sarah L Davis (1)

NIH funding

2018 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186691 (1), UM1CA186704 (1), UM1CA186716 (1)